Combined anti-cytokine therapy is a promising therapeutic approach for uncontrolled steroid-resistant asthma. In this regard, simultaneous blockade of IL-4 and IL-13 signaling by Dupilumab (anti-IL-4Ra monoclonal antibody) was recently approved for severe eosinophilic asthma. However, no therapeutic options for neutrophilic asthma are currently available. Recent advances in our understanding of asthma pathogenesis suggest that both IL-6 and TNF may represent potential targets for treatment of severe neutrophilic asthma. Nevertheless, the efficacy of simultaneous pharmacological inhibition of TNF and IL-6 in asthma was not yet studied. To evaluate the potency of combined cytokine inhibition, we simultaneously administrated IL-6 and TNF inhibitors to BALB/c mice with HDM-induced asthma. Combined IL-6/TNF inhibition, but not individual blockade of these two cytokines, led to complex anti-inflammatory effects including reduced Th2-induced eosinophilia and less prominent Th17/Th1-mediated neutrophilic infiltrate in the airways. Taken together, our results provide evidence for therapeutic potential of combined IL-6/TNF inhibition in severe steroid-resistant asthma.
Lipopolysaccharide (LPS)-induced lung injury is the most commonly used mouse model of acute lung inflammation that simulates the development of respiratory distress syndrome in humans. The effects of acute LPS-induced airway inflammation are well studied and associated with the neutrophil accumulation in bronchoalveolar lavage fluid (BALF), local and systemic production of proinflammatory cytokines and narrowing of the airways. Recent studies demonstrated the presence of pulmonary fibrosis characterized by increased fibroblast proliferation and excess extracellular matrix deposition in late phase of acute lung inflammation caused by LPS exposure. This work describes an experimental model of acute lung injury induced by a single aerosol injection of LPS as a reproducible in vivo model of pulmonary fibrosis. To induce lung injury, C57BL/6 mice were placed in a chamber and exposed to an aerosol containing 10 mg of LPS using an Aeroneb Lab Nebulizer delivery system. We found that 5 weeks after a single nebulized LPS administration, mice have increased production of IL-6 in BALF. Although the frequency of neutrophils was not altered, there was a decrease in the percentage of alveolar macrophages at 5 weeks after LPS exposure, indicating continued lung inflammation. Several weeks after aerosolized LPS challenge, IL-10 production in BALF was increased, as well as expression of Tgfb1, Col1a1, Il13 and Acta2, and collagen deposition in lung tissue compared to mice with acute lung inflammation. Thus, the single nebulized LPS administration represents a relevant, reproducible and physiologic model in mice allowing to investigate the mechanisms of pulmonary fibrosis development and help in the search for new therapeutic agents and approaches.
Fibrosis is a pathological form of tissue remodeling driven by excessive deposition of extracellular matrix (ECM). Unlike physiological tissue repair, fibrosis arises from persistent myofibroblast activation and unresolved inflammation. Chronic inflammation can both initiate fibrotic remodeling and be sustained by the resulting tissue alterations, supporting the view of fibrosis as an immune-mediated process. Fibrogenesis is fundamentally shaped by interactions between macrophages and fibroblasts. Polarized macrophages can modulate fibroblast activity and promote their differentiation into myofibroblasts. IL-6 is an important mediator of macrophage–fibroblast communication and has been implicated in fibrotic diseases affecting multiple organs. Notably, the effects of IL-6 are highly context-dependent. During acute injury, IL-6 can promote tissue repair by stimulating epithelial proliferation and angiogenesis, whereas persistent IL-6 signaling in chronic inflammation can become a major driver of fibrosis. IL-6 is also a prominent component of the senescence-associated secretory phenotype (SASP), providing a mechanistic link between fibrosis, cellular senescence, and inflammaging. In this review, we provide an integrated overview of the role of IL-6 in macrophage–fibroblast interactions during pulmonary fibrogenesis, with particular emphasis on its context-dependent functions at the interface between tissue repair and pathological tissue remodeling. We also discuss current therapeutic strategies aimed at targeting IL-6 signaling.
Alveolar macrophages (AMs) comprise the predominant immune cell population in the lungs, maintaining homeostasis and providing the first line of immune defense against various respiratory diseases. Most studies focus on macrophages differentiated from bone marrow precursors in vitro. However, the ontogeny of the tissue-resident macrophages and the lung microenvironment significantly determine their properties and functions, fundamentally distinguishing AMs from the cells derived in vitro. The use of AMs ex vivo, which maximally preserves their original phenotype and proliferative potential, is the most physiological and informative approach for studying various aspects of innate immune responses in lung diseases. Improving methods for their isolation and culturing remains an important task for obtaining relevant data on the functions of these cells. In this study, we evaluated the effect of enzymatic treatment, the most common method for detaching cultured AMs, on their phenotype. It was found that enzymatic treatment led to the decrease in production of GM-CSF and VEGF by the AMs mediators of myeloid cell differentiation and maturation, and angiogenesis, respectively, both in the non-activated state and in response to one of the most common allergens – house dust mite extract (HDM). Enzymatic treatment promoted the formation of a pro-inflammatory phenotype, manifested by the increased production of IL-6, as well as chemokines CCL4 and CCL5, which attract monocytes and lymphocytes to the site of inflammation, along with the trend toward increased expression of the M1-associated genes such as Nos2 and Cd38, in response to HDM. Thus, enzymatic detachment of the tissue-resident AMs promotes M1 polarization, which predetermines a more pronounced response to the allergen in vitro. The presented data highlight disadvantages of the enzymatic treatment of AMs, increasing the risk of artifacts, and affecting reliability of the experimental results.